Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Dec 10

PMID 34884813

Citations 30

Authors

Xi-Dian Tang

Tian-Tian Ji

Jia-Rui Dong

Hao Feng

Feng-Qiang Chen

Xi Chen

Hui-Ying Zhao

De-Kun Chen

Wen-Tao Ma

Affiliations

Soon will be listed here.

Abstract

Cytokine storm is a phenomenon characterized by strong elevated circulating cytokines that most often occur after an overreactive immune system is activated by an acute systemic infection. A variety of cells participate in cytokine storm induction and progression, with profiles of cytokines released during cytokine storm varying from disease to disease. This review focuses on pathophysiological mechanisms underlying cytokine storm induction and progression induced by pathogenic invasive infectious diseases. Strategies for targeted treatment of various types of infection-induced cytokine storms are described from both host and pathogen perspectives. In summary, current studies indicate that cytokine storm-targeted therapies can effectively alleviate tissue damage while promoting the clearance of invading pathogens. Based on this premise, "multi-omics" immune system profiling should facilitate the development of more effective therapeutic strategies to alleviate cytokine storms caused by various diseases.

Citing Articles

Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights.

Shah D, Chorawala M, Pandya A, Kothari N, Prajapati B, Parekh P Curr Med Sci. 2024; 44(6):1155-1174.

PMID: 39676146 DOI: 10.1007/s11596-024-2936-5.

Immune regulation and organ damage link adiponectin to sepsis.

Zhang L, Lin Y, Zhang Z, Chen Y, Zhong J Front Immunol. 2024; 15:1444884.

PMID: 39664383 PMC: 11632310. DOI: 10.3389/fimmu.2024.1444884.

Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced ‎oxidative stress and inflammation in mice‎: ‎An study.

Al-Naimi M, Abu-Raghif A, Fawzi H Toxicol Rep. 2024; 13:101808.

PMID: 39640902 PMC: 11617758. DOI: 10.1016/j.toxrep.2024.101808.

Interleukins in the pathogenesis of influenza and other acute respiratory viral infections.

Andreychyn M, Melnyk L, Zavidniiuk N, Nychyk N, Iosyk I Epidemiol Infect. 2024; 152:e109.

PMID: 39344895 PMC: 11450507. DOI: 10.1017/S0950268824001109.

Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes.

Armstrong A, Tang Y, Mukherjee N, Zhang N, Huang G Front Immunol. 2024; 15:1448201.

PMID: 39318634 PMC: 11420043. DOI: 10.3389/fimmu.2024.1448201.

References

Erbil B, Ersoy G, Ozkutuk A, Akarca F, Korkmaz T, Demir O . The effects of oral antibiotics on infection prophylaxis in traumatic wounds. Ulus Travma Acil Cerrahi Derg. 2014; 20(4):231-5. DOI: 10.5505/tjtes.2014.63993. View

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Sun J, Zhang W, Chen W, Wang X, Mu X . Effects of early enteral nutrition on Th17/Treg cells and IL-23/IL-17 in septic patients. World J Gastroenterol. 2019; 25(22):2799-2808. PMC: 6580355. DOI: 10.3748/wjg.v25.i22.2799. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Gopal R, Mendy A, Marinelli M, Richwalls L, Seger P, Patel S . Peroxisome Proliferator-Activated Receptor Gamma (PPAR) Suppresses Inflammation and Bacterial Clearance during Influenza-Bacterial Super-Infection. Viruses. 2019; 11(6). PMC: 6630660. DOI: 10.3390/v11060505. View

Chen J, Zhang L, Hou H, Xu L, Ji K . Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review). Exp Ther Med. 2020; 21(1):24. PMC: 7690237. DOI: 10.3892/etm.2020.9456. View

Isolauri E, Kirjavainen P, Salminen S . Probiotics: a role in the treatment of intestinal infection and inflammation?. Gut. 2002; 50 Suppl 3:III54-9. PMC: 1867676. DOI: 10.1136/gut.50.suppl_3.iii54. View

Oldstone M, Rosen H . Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol. 2014; 378:129-47. PMC: 7121493. DOI: 10.1007/978-3-319-05879-5_6. View

Martin L, Schmitz S, De Santis R, Doemming S, Haase H, Hoeger J . Peptide 19-2.5 inhibits heparan sulfate-triggered inflammation in murine cardiomyocytes stimulated with human sepsis serum. PLoS One. 2015; 10(5):e0127584. PMC: 4449035. DOI: 10.1371/journal.pone.0127584. View

10.

Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2):181-93. PMC: 4752723. DOI: 10.1016/j.chom.2016.01.007. View

11.

AbdAllah N, Toraih E, Al Ageeli E, Elhagrasy H, Gouda N, Fawzy M . MYD88, NFKB1, and IL6 transcripts overexpression are associated with poor outcomes and short survival in neonatal sepsis. Sci Rep. 2021; 11(1):13374. PMC: 8238937. DOI: 10.1038/s41598-021-92912-7. View

12.

Ma J, Li Y, Zhang S, Fu S, Ye X . MiR-590-3p Attenuates Acute Kidney Injury by Inhibiting Tumor Necrosis Factor Receptor-Associated Factor 6 in Septic Mice. Inflammation. 2018; 42(2):637-649. DOI: 10.1007/s10753-018-0921-5. View

13.

Lee I, Lee J, Kong S . A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations. Infect Genet Evol. 2020; 85:104507. PMC: 7448771. DOI: 10.1016/j.meegid.2020.104507. View

14.

Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco V . Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A. 2020; 117(32):18951-18953. PMC: 7430998. DOI: 10.1073/pnas.2009017117. View

15.

Reyes M, Filbin M, Bhattacharyya R, Billman K, Eisenhaure T, Hung D . An immune-cell signature of bacterial sepsis. Nat Med. 2020; 26(3):333-340. PMC: 7235950. DOI: 10.1038/s41591-020-0752-4. View

16.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

17.

Qiu D, Chu X, Hua L, Yang Y, Li K, Han Y . Gpr174-deficient regulatory T cells decrease cytokine storm in septic mice. Cell Death Dis. 2019; 10(3):233. PMC: 6408576. DOI: 10.1038/s41419-019-1462-z. View

18.

Dravid A, Kashiva R, Khan Z, Memon D, Kodre A, Potdar P . Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India. Medicine (Baltimore). 2021; 100(29):e26705. PMC: 8294888. DOI: 10.1097/MD.0000000000026705. View

19.

Huang L, Zhao X, Qi Y, Li H, Ye G, Liu Y . Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. Cell Mol Immunol. 2020; 17(10):1092-1094. PMC: 7484610. DOI: 10.1038/s41423-020-00522-6. View

20.

Kutateladze M, Adamia R . Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010; 28(12):591-5. DOI: 10.1016/j.tibtech.2010.08.001. View